Vertex Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	11,693	11,020	9,869	8,931	7,573	6,203
Other Revenue	30.7	-	-	-	1	2.9
Revenue	11,723	11,020	9,869	8,931	7,574	6,206
Revenue Growth (YoY)	10.33%	11.66%	10.51%	17.91%	22.06%	49.08%
Cost of Revenue	5,543	5,161	4,425	3,608	2,842	2,381
Gross Profit	6,180	5,859	5,444	5,323	4,732	3,825
Selling, General & Admin	1,644	1,464	1,137	944.7	840.1	770.5
Operating Expenses	1,644	1,464	1,137	944.7	840.1	770.5
Operating Income	4,536	4,395	4,308	4,378	3,892	3,054
Interest Expense	-12.8	-30.6	-44.1	-54.8	-61.5	-58.2
Interest & Investment Income	497.2	598.1	614.7	144.6	4.9	22.2
Currency Exchange Gain (Loss)	-38.8	-27.3	-24.6	-15.1	-13.9	-16.1
Other Non Operating Income (Expenses)	25.2	-49.3	9.3	-0.6	1.7	0.8
EBT Excluding Unusual Items	5,007	4,886	4,863	4,453	3,824	3,003
Gain (Loss) on Sale of Investments	-15.5	-9.5	-7.5	-149.1	17.1	311.9
Asset Writedown	-379	-	-	-13	-	-
Other Unusual Items	-	0.5	51.6	57.5	3.1	-13.1
Pretax Income	4,449	248.5	4,380	4,232	2,730	3,117
Income Tax Expense	773.6	784.1	760.2	910.4	388.3	405.2
Earnings From Continuing Operations	3,675	-535.6	3,620	3,322	2,342	2,712
Net Income to Company	3,675	-535.6	3,620	3,322	2,342	2,712
Net Income	3,675	-535.6	3,620	3,322	2,342	2,712
Net Income to Common	3,675	-535.6	3,620	3,322	2,342	2,712
Net Income Growth	-	-	8.96%	41.84%	-13.63%	130.43%
Shares Outstanding (Basic)	257	258	258	256	258	260
Shares Outstanding (Diluted)	258	258	261	259	260	263
Shares Change (YoY)	0.11%	-1.00%	0.54%	-0.31%	-1.33%	1.04%
EPS (Basic)	14.32	-2.08	14.05	12.97	9.09	10.44
EPS (Diluted)	14.22	-2.08	13.89	12.82	9.01	10.29
EPS Growth	-	-	8.35%	42.29%	-12.44%	128.16%
Free Cash Flow	3,337	-790.3	3,337	3,925	2,409	2,994
Free Cash Flow Per Share	12.92	-3.06	12.81	15.15	9.27	11.37
Gross Margin	52.72%	53.17%	55.16%	59.60%	62.48%	61.63%
Operating Margin	38.70%	39.88%	43.65%	49.03%	51.39%	49.21%
Profit Margin	31.35%	-4.86%	36.68%	37.20%	30.92%	43.70%
Free Cash Flow Margin	28.47%	-7.17%	33.81%	43.95%	31.80%	48.24%
EBITDA	4,712	4,577	4,477	4,527	4,018	3,164
EBITDA Margin	40.19%	41.53%	45.36%	50.69%	53.05%	50.98%
D&A For EBITDA	175.4	182	169.5	148.3	125.6	109.5
EBIT	4,536	4,395	4,308	4,378	3,892	3,054
EBIT Margin	38.70%	39.88%	43.65%	49.03%	51.39%	49.21%
Effective Tax Rate	17.39%	315.53%	17.36%	21.51%	14.22%	13.00%
Revenue as Reported	703.2	-	-	-	7,574	6,206

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.